This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Why You Should Add Merit Medical (MMSI) to Your Portfolio
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, courtesy of its solid prospects.
Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis
by Zacks Equity Research
Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
by Zacks Equity Research
LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
by Zacks Equity Research
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
Hologic (HOLX) Gets Additional FDA Nod, to Aid HIV Testing
by Zacks Equity Research
Additional FDA approval for Hologic's (HOLX) molecular diagnostic test is expected to aid in the diagnosis of HIV infection.
Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts
by Zacks Equity Research
Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
Enjoy Thanksgiving with a Wall Street Bonanza
by Nalak Das
It will be prudent to invest in large-cap stocks with a favorable Zacks Rank that are members of any of the three large-cap indexes. These are DHR, UPS, NVDA, MSFT, TGT, TMO, DE, FDX.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Q3 Earnings Scorecard and Analyst Reports for Tesla, JPMorgan & Comcast
by Sheraz Mian
We have provided a real-time scorecard of the Q3 earnings season, in addition to featuring new research reports on Tesla (TSLA), JPMorgan Chase (JPM) and Comcast (CMCSA).
Zacks.com featured highlights include: TeleTech, Thermo Fisher, Best Buy, ParkerHannifin and Nu Skin
by Zacks Equity Research
Zacks.com featured highlights include: TeleTech, Thermo Fisher, Best Buy, ParkerHannifin and Nu Skin
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
by Zacks Equity Research
Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Ecolab (ECL) Gets EPA Nod for Biofilm Disinfectant Virasept
by Zacks Equity Research
Ecolab's (ECL) Virasept has been developed to combat bacterial growth in hospitals.
NEOGEN (NEOG), Transnetyx Partner to Advance Mouse Genotyping
by Zacks Equity Research
NEOGEN (NEOG) aims to better serve the biomedical research community with a comprehensive and affordable solution for the genetic background testing of their mouse models via the partnership.
COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus
by Rimmi Singhi
With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
5 Top Dividend Growth Stocks to Buy on the Cheap
by Sweta Killa
Honing in on stocks with a history of dividend growth leads to a healthy portfolio, with greater scope of capital appreciation as opposed to simple dividend-paying stocks or those with high yields.